Affiliation:
1. Faculty of Medicine, University of Belgrade, 11 000 Belgrade, Serbia
2. University Clinical Hospital Center Bezanijska Kosa, Faculty of Medicine, University of Belgrade, 11 000 Belgrade, Serbia
Abstract
(1) Background: The aim of this study was to assess the incidence and the risk factors for healthcare-associated Clostridioides difficile infection (HA-CDI) in patients with COVID-19 and without this infection. (2) Methods: A single-center, prospective observational study was conducted at the University Clinical Hospital Center in Belgrade, Serbia, from January 2019 to December 2021. The entire hospital was a COVID-dedicated hospital for 12 months during the study period. The incidence density rates and risk factors for HA-CDI in patients with and without COVID-19 are presented. (3) Results: The incidence rates of HA-CDIs were three times higher in patients with COVID-19. The HA-CDI–COVID-patients were younger (69.9 ± 12.6 vs. 72.5 ± 11.6; p = 0.017), admitted from another hospital (20.5% vs. 2.9; p < 0.001), had antimicrobial therapy before CDI (99.1% vs. 91.3%, p < 0.001), received two or more antibiotics (p = 0.030) during a longer period (p = 0.035), received proton pump inhibitors (95.9% vs. 50.0%, p < 0.001) during a longer period (p = 0.012) and steroids (32.8% vs. 20.4%, p < 0.001). During the last month before their current hospitalization, a higher percentage of patients without COVID-19 disease were hospitalized in our hospital (p < 0.001). Independent predictors for HA-CDIs in patients with COVID-19 were admission from another hospital (p = 0.003), the length of antibiotic administration (0.020), and the use of steroids in therapy (p < 0.001). The HA-CDI predictors in the non-COVID patients were older age (p = 0.017), advanced-stage renal failure (p = 0.005), chemotherapy (p = 0.003), and a low albumin level (0.005). (4) Conclusion: Higher incidence rates of HAI-CDIs in COVID-19 patients did not occur due to reduced infection control precautions and hygiene measures but due to antibiotic therapy and therapy with other drugs used during the pandemic.
Subject
Virology,Microbiology (medical),Microbiology
Reference48 articles.
1. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prevot 1938;Lawson;Anaerobe,2016
2. Finn, E., Andersson, F.L., and Madin-Warburton, M. (2021). Burden of Clostridioides difficile infection (CDI)—A systematic review of the epidemiology of primary and recurrent CDI. BMC Infect. Dis., 21.
3. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes;Guh;N. Engl. J. Med.,2020
4. European Centre for Disease Prevention and Control (2022). Clostridioides (Clostridium) Difficile Infections Annual Epidemiological Report for 2016–2017, ECDC. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/clostridioides-clostridium-difficile-infections.pdf.
5. Perić, A., Rančić, N., Dragojević-Simić, V., Milenković, B., Ljubenović, N., Rakonjac, B., Begović-Kuprešanin, V., and Šuljagić, V. (2022). Association between Antibiotic Use and Hospital-Onset Clostridioides difficile Infection in University Tertiary Hospital in Serbia, 2011-2021: An Ecological Analysis. Antibiotics, 11.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献